Kura Oncology, Inc.
Here’s whether Kura Oncology, Inc. (KURA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.98% over 10 days); strong 1-year return of +59.8%; 3-month momentum positive (+5.7%); rising volume confirms the move (1.55x 30d avg). Concerns: RSI 78 — overbought, elevated pullback risk. Currently 7.8% off its 52-week high. Score: +6/7.
KURA is in a confirmed uptrend, trading above both its 50-day ($10.47) and 200-day ($9.68) moving averages. With an RSI of 77.7, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +59.8% compares to +20.5% for SPY (beat the market by 39.3%).